Bezafibrate in skeletal muscle fatty acid oxidation disorders: A randomized clinical trial

Neurology

Volumn 82, Issue 7, 2014, Pages 607-613

  Ørngreen, Mette Cathrine ^a   Madsen, Karen Lindhardt ^a   Preisler, Nicolai ^a   Andersen, Grete ^a   Vissing, John ^a   Laforêt, Pascal ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; BEZAFIBRATE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE II; CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; PALMITIC ACID; STABLE ISOTOPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CALORIMETRY; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; ENERGY EXPENDITURE; ENZYME DEFICIENCY; EXERCISE; EXERCISE TOLERANCE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FEMALE; HEART RATE; HUMAN; MALE; MEDICATION COMPLIANCE; METABOLIC EQUIVALENT; MIDDLE AGED; MYOPATHY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; YOUNG ADULT;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ADOLESCENT; ADULT; AGED; BEZAFIBRATE; CARNITINE O-PALMITOYLTRANSFERASE; CLINICAL PROTOCOLS; CROSS-OVER STUDIES; FATTY ACIDS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM, INBORN ERRORS; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; MUSCULAR DISEASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895727764     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000118     Document Type: Article

References (24)

1. Orngreen MC, Duno M, Ejstrup R, et al. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol 2005;57:60-66.
2. Orngreen MC, Norgaard MG, Sacchetti M, van Engelen BG, Vissing J. Fuel utilization in patients with very long-chain acyl-CoA dehydrogenase deficiency. Ann Neurol 2004;56:279-283.
3. Orngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003;61:559-561.
4. Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab 2005;90:1791-1797.
5. Djouadi F, Aubey F, Schlemmer D, et al. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 2005;14:2695-2703.
6. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
7. Lemberger T, Braissant O, Juge-Aubry C, et al. PPAR tissue distribution and interactions with other hormonesignaling pathways. Ann NY Acad Sci 1996;804:231-251.
8. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996;12:335-363.
9. Abshagen U, Sporl-Radun S, Marinow J. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur J Clin Pharmacol 1980;17:305-308.
10. Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987;33:539-576.
11. Djouadi F, Aubey F, Schlemmer D, et al. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis 2006;29:341-342.
12. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009;360:838-840.
13. Bonnefont JP, Bastin J, Laforet P, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010;88:101-108.
14. Orngreen MC, Jeppesen TD, Andersen ST, et al. Fat metabolism during exercise in patients with McArdle disease. Neurology 2009;72:718-724.
15. Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 1981;30:936-940.
16. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-98.
17. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003;349:2503-2509.
18. Jakicic JM, Marcus M, Gallagher KI, et al. Evaluation of the SenseWear Pro Armband to assess energy expenditure during exercise. Med Sci Sports Exerc 2004;36:897-904.
19. Astrand PO, Rodahl K, Dahl HA, Stromme SB. Textbook of Work Physiology: Physiological Bases of Exercise. Champaign, IL: Human Kinetics; 2003.
20. Goa KL, Barradell LB, Plosker GL. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52:725-753.
21. Haemmerle G, Moustafa T, Woelkart G, et al. ATGLmediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 2011; 17:1076-1085.
22. Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 2012;21:1124-1137.
23. Wenz T, Wang X, Marini M, Moraes CT. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2011;15:2317-2325.
24. Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 2012;21:526-535.